{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:05:16Z","timestamp":1780664716212,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bmc.2021.116523","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T01:56:56Z","timestamp":1637546216000},"page":"116523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro"],"prefix":"10.1016","volume":"53","author":[{"given":"Yong","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbiao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116523_b0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2021.116523_b0010","first-page":"2781","article-title":"Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?","volume":"24","author":"Ceccarelli","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.bmc.2021.116523_b0015","first-page":"2162","article-title":"Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches?","volume":"24","author":"Perrella","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.bmc.2021.116523_b0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.bmc.2021.116523_b0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.semarthrit.2003.09.012","article-title":"Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature","volume":"33","author":"Nord","year":"2004","journal-title":"Semin Arthritis Rheu"},{"key":"10.1016\/j.bmc.2021.116523_b0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2021.116523_b0035","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2021.116523_b0040","doi-asserted-by":"crossref","unstructured":"Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom; 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/threat-assessment-brief-rapid-increase-sars-cov-2-variant-united-kingdom#no-link [accessed 2021-01-11].","DOI":"10.23880\/OAJPRS-16000132"},{"key":"10.1016\/j.bmc.2021.116523_b0045","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard; 2021. https:\/\/covid19.who.int\/ [accessed 2021-01-11]."},{"key":"10.1016\/j.bmc.2021.116523_b0050","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","author":"Cannalire","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116523_b0055","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116523_b0060","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acsinfecdis.0c00874","article-title":"Early returns on small molecule therapeutics for SARS-CoV-2","volume":"7","author":"Namchuk","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2021.116523_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmc.2021.116523_b0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2021.116523_b0075","article-title":"Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial","volume":"8","author":"McCoy","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.bmc.2021.116523_b0080","first-page":"e13492","article-title":"Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial","volume":"13","author":"Cadegiani","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.bmc.2021.116523_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkab318","article-title":"Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study","author":"Khoo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmc.2021.116523_b0090","doi-asserted-by":"crossref","first-page":"105122","DOI":"10.1016\/j.antiviral.2021.105122","article-title":"A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents","volume":"192","author":"Do","year":"2021","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2021.116523_b0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bmc.2021.116523_b0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2021.116523_b0105","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Revista panamericana de salud publica = Pan Am J Publ Health"},{"key":"10.1016\/j.bmc.2021.116523_b0110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"367","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2021.116523_b0115","first-page":"115","article-title":"Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review","volume":"42","author":"Parhizgar","year":"2017","journal-title":"Iran J Med Sci"},{"key":"10.1016\/j.bmc.2021.116523_b0120","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bmc.2021.116523_b0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BioScience Trends"},{"key":"10.1016\/j.bmc.2021.116523_b0130","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Xueting Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2021.116523_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.bmc.2021.116523_b0140","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2021.116523_b0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jir.2014.0038","article-title":"Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery","volume":"35","author":"Wang","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.bmc.2021.116523_b0150","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.bmc.2021.116523_b0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2021.116523_b0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bmc.2021.116523_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.bmc.2021.116523_b0170","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bmc.2021.116523_b0175","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.dsx.2020.08.033","article-title":"No benefit of hydroxychloroquine in COVID-19: results of systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Pathak","year":"2020","journal-title":"Diab Metab Synd: Clin Res Rev"},{"key":"10.1016\/j.bmc.2021.116523_b0180","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bmc.2021.116523_b0185","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"Bmj-British Med J"},{"key":"10.1016\/j.bmc.2021.116523_b0190","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"Jama Netw Open"},{"key":"10.1016\/j.bmc.2021.116523_b0195","unstructured":"\u201cSolidarity\u201d clinical trial for COVID-19 treatments; 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments [accessed 2021-01-11]."},{"key":"10.1016\/j.bmc.2021.116523_b0200","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates","volume":"585","author":"Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2021.116523_b0205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/chir.530060420","article-title":"Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate","volume":"6","author":"Tett","year":"1994","journal-title":"Chirality"},{"key":"10.1016\/j.bmc.2021.116523_b0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2125.1993.tb05897.x","article-title":"Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate","volume":"36","author":"McLachlan","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2021.116523_b0215","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/j.1552-4604.1994.tb01986.x","article-title":"Hematologic disposition of hydroxychloroquine enantiomers","volume":"34","author":"Brocks","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2021.116523_b0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2125.1995.tb05768.x","article-title":"Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects","volume":"40","author":"Ducharme","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2021.116523_b0225","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.drudis.2020.04.021","article-title":"Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19","volume":"25","author":"D'Acquarica","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2021.116523_b0230","article-title":"Enantiomers of chloroquine and hydroxychloroquine exhibit different activities against SARS-CoV-2 in vitro, evidencing S-hydroxychloroquine as a potentially superior drug for COVID-19","author":"Li","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.bmc.2021.116523_b0235","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/0957-4166(94)80090-1","article-title":"A practical synthesis of the enantiomers of hydroxychloroquine","volume":"5","author":"Blaney","year":"1994","journal-title":"Tetrahedron Asymmetry"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621005319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621005319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:16:11Z","timestamp":1760836571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621005319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"alternative-id":["S0968089621005319"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116523","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116523"}}